Treatment future and incentives
55:24–56:25 · 61s
Fox flags a worrying trend: pharma invests less in immune-retraining approaches and more in lifelong symptom blockers, shaping allergy care’s direction.
55:24–56:25 · 61s
Fox flags a worrying trend: pharma invests less in immune-retraining approaches and more in lifelong symptom blockers, shaping allergy care’s direction.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.